

Crohn's Disease Ulcerative Colitis

**A study to look at the long-term safety of a medicine, efmarodocokin alfa, in people with ulcerative colitis**

An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease

**Trial Status**  
Terminated

**Trial Runs In**  
14 Countries

**Trial Identifier**  
NCT03650413 2017-004997-32  
GA40209

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This clinical trial was done to study a new medicine called, “efmarodocokin alfa”, for the treatment of patients with ulcerative colitis. This was a Phase 2 open-label extension study to find out the long-term safety and tolerability of efmarodocokin alfa in patients with moderate to severe ulcerative colitis. It was carried out at 66 study centers in fourteen countries.

<b>Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)</b>	<b>Phase 2</b>
Sponsor	Phase

**NCT03650413 2017-004997-32 GA40209**  
Trial Identifiers

***Eligibility Criteria:***

<b>Gender</b> All	<b>Age</b> ≥ 18 Years & ≤ 80 Years	<b>Healthy Volunteers</b> No
----------------------	---------------------------------------	---------------------------------